Badanie autokorelacji przestrzennej krwiodawstwa w Polsce

Aim of this study is to investigate the presence of spatial dependence in the level of development of the blood donation. Analysis of spatial data will identify the similarities and differences between provinces. Using the tools of spatial statistics will be revised hypothesis of the presence of spatial autocorrelation. Using local statistics there will be highlighted the major development centers of the blood donation in the country. The possibility of using measures of spatial autocorrelation will be shown by the example of analysis of diversity of the population per one blood donor, per one blood unit for particular provinces or diversity in the number of hospital beds per one blood unit for provinces. Then there will be formed the synthetic development measure of provinces on the basis of Hellwig's synthetic development measure. Assumed that determined development measure will illustrate overall situation of blood donation in particular province

Amyloidoza łańcuchów lekkich immunoglobulin z punktu widzenia kardiologa

Light-chain amyloidosis (amyloidosis AL) is diagnosed in approx. 70% of patients with cardiac amyloidosis. This type of amyloidosis has the worst prognosis, especially if the diagnosis is made in advanced stages. The majority of patients are referred to a cardiologist, but unfortunately only every fifth of them has the proper diagnosis. Therefore, strategies promoting early diagnosis are important. One of them is the measurement of serum free light chains concentration in every patient with heart failure with preserved ejection fraction. The acknowledgement of free light chains (FLCs) cardiotoxicity rendered the picture of AL amyloidosis from infiltrative cardiomyopathy into a toxic one. Best improvement in regard to heart failure is achieved upon hematological treatment resulting in decrease of FLCs concentration. Therefore, cardiological treatment is rather a supportive therapy. The role of cardiologist is the rapid diagnosis of the disease and referral of the patient to the hematologist. The standard heart failure treatment encompassing use of beta-blockers and angiotensin converting enzyme inhibitors aggravates orthostatic hypotension and congestion. Instead, up-to-date hematological treatment improves the prognosis of AL amyloidosis markedly, as long as early diagnosis is made.Amyloidozę łańcuchów lekkich (amyloidozę AL) rozpoznaje się u około 70% pacjentów z amyloidozą serca. Ta postać choroby wiąże się z najgorszym rokowaniem, szczególnie jeśli wykrywa się ją na zaawansowanym etapie. Kardiolog jest najczęściej odwiedzanym specjalistą przez pacjentów z amyloidozą AL. Niestety tylko u co piątego pacjenta jest stawiana właściwa diagnoza. Dlatego ważne jest, aby promować działania umożliwiające wczesne stwierdzenie choroby. Należy do nich oznaczanie wolnych łańcuchów lekkich (FLC) w surowicy u pacjentów z niewydolnością sercaz zachowaną frakcją wyrzutową. Wykazanie kardiotoksycznej roli FLC zmieniło postrzeganie amyloidozy AL jako choroby polegającej wyłącznie na pozakomórkowym gromadzeniu się nieprawidłowych złogów białkowych. Największą poprawę funkcji serca uzyskuje się, obniżając stężenie FLC w surowicy poprzez leczenie cytoredukcyjne. Leczenie kardiologiczne ma znaczenie uzupełniające. Rola kardiologa sprowadza się do jak najszybszego rozpoznania choroby i przekazania pacjenta do hematologa. Standardowa farmakoterapia niewydolności serca, obejmująca beta-adrenolityki i inhibitory konwertazy angiotensyny, u pacjentów z amyloidozą wywołuje nasilenie hipotensji ortostatycznej i objawów zastoinowych. Natomiast dzięki nowoczesnemu leczeniu cytoredukcyjnemu i antyamyloidowemu istotnie poprawiły się wyniki leczenia, pod warunkiem wczesnego rozpoznania amyloidozy AL

Rating life expectancy in good health of polish population using summary measures of population health

Not only has the quantity (i.e. in terms of the extension of the duration of life) become the aim of action on the health plane, but also the qualitative, or extending the duration of lifein good health, which is not accompanied by disability and life activity limitations due to health. To estimate changes in health status of the population, implemented health programs and medical care needed new health measures. Meters beyond the negative indicators on mortality and life expectancy, but also including other dimensions of health status and quality of life related to health. This group of measures is called summary measures of population health and is divided into two main parts: the measure of the health expectancies and measures of health gap. The aim of the article is a presentation and use of selected health summary measures for estimating life expectancy in good health of Polish population against the background of the population of the European Union countries. Data from the Central Statistical Office and the European Statistical System as well as database and publications prepared by the World Health Organization and the United Nations will be a base of empirical analysis

Rodzina modeli Lee-Cartera

This paper presents a proposal for the application of selected models of the group of models using the Lee and Carter methodology for forecasting mortality rates. These include the original Lee-Carter, the Lee-Miller (2001) and Booth-Maindonald-Smith (2002) variants, and the more flexible Hyndman-Ullah (2005) and de Jong (2006) extensions. Based on estimates of mortality rates derived from the selected models was verified the ability to use these models to estimate mortality rates in Poland

Health Gap and Gap in Population as a Risk Measures Functioning in Health

The aim of the action at the level of healthcare has become not only a quantitative dimension, which means extending the duration of life, but also qualitative, extension of the duration of life in good health, which is not accompanied by disability and activity limitation due to health living. Health gap is defined as the difference between the current state of health in the population and the condition termed full health. In contrast, the area between the survival curve and the estimated population norm for survival is called a gap in the population, which are the losses resulting from mortality before the expected age. The aim of this paper is to evaluate the size of the gap of health and gaps in the population and to determine the relationship between them as the risk function in health

The Aging of the Silesian Agglomeration

The progress of the aging population and its diversity associated with space and time, the interaction with the socio-economic situation requires the use of alternative measures of analysis of this phenomenon. The aim of this paper is to analyze the dynamics of differences and the advancement of the aging population of the Silesian agglomeration. Recognition reveals the diversity heterogeneity in the population structure of cities and in the course of demographic change

Use of omega measure for the assessment survival time in healthy

Lata życia w zdrowiu to jedna z miar zaproponowanych do monitorowania stanu zdrowia w krajach europejskich. Metoda ta oparta została na dwóch miarach: częstości występowania niepełnosprawności w populacji w określonym wieku oraz umieralności. Celem artykułu jest wykorzystanie miary ryzyka Omega do oceny ryzyka czasu przeżycia oraz czasu przeżycia w zdrowiu. Miara Omega zaliczana jest do miar kwantylowych, gdyż zakłada występowanie pewnego punktu progowego, dzielącego zbiór realizacji zmiennej na obszar zysku oraz obszar strat. W badaniu jako zysk rozumiana jest liczba lat życia bez niesprawności, natomiast stratą określana jest liczba lat życia z niesprawnością.Years of healthy life is one of the measures proposed to monitor the state of health in European countries. This method is based on two measures: the frequency of a disability in the population at a certain age and mortality. The aim of this lecture is to use Omega risk measures to risk assessment of survival time and survival time in health. It is counted to quantile measures because it assumes the existence of a threshold point dividing the set of variables into the profit and loss area. In this study, the number of years of life without disability is understood as a profit, and the loss is defined by the number of years of life with disability

Use of summary measures of lack of health to assess impact of specific diseases and disability for health condition in Poland

Pomimo że ciągle podkreśla się wagę chorobowości i niesprawności, debaty na temat polityki zdrowotnej zbyt często skupiają się na umieralności. Jedną z przyczyn takiego stanu rzeczy jest brak porównywalnych informacji dotyczących wyników zdrowotnych innych niż zgon, które mogłyby być zestawione z informacją na temat obciążenia przedwczesną umieralnością. W celu obliczenia czasu przeżytego z pewnym stanem zdrowotnym w sposób porównywalny ze standaryzowanym czasem utraconym na skutek przedwczesnej umieralności konieczny jest duży stopień uproszczenia. Celem pracy jest prezentacja lat życia skorygowanych niesprawnością DALY jako miary braku zdrowia oraz jej zastosowanie w szacowaniu obciążenia chorobami. W części empirycznej zaprezentowano zmiany, jakie dokonały się w obciążeniu chorobami populacji Polski między 1990 a 2010 r.Despite that morbidity and lack of health is always in concern, the debate on health policy is too often focus on mortality. One of the reasons for this is the lack of comparable information on health outcomes with premature mortality. In order to calculate the time lived with a certain state of health in a way comparable to the standardized time lost due to premature mortality, it is necessary high degree of simplification. The aim of the work is the presentation of life year adjusted with disability DALY as a measure lack of health and its use in estimating the burden of disease. The empirical part presents the changes that have occurred in the Polish population disease burden between 1990 and 2010

Badanie autokorelacji przestrzennej krwiodawstwa w Polsce

Aim of this study is to investigate the presence of spatial dependence in the level of development of the blood donation. Analysis of spatial data will identify the similarities and differences between provinces. Using the tools of spatial statistics will be revised hypothesis of the presence of spatial autocorrelation. Using local statistics there will be highlighted the major development centers of the blood donation in the country. The possibility of using measures of spatial autocorrelation will be shown by the example of analysis of diversity of the population per one blood donor, per one blood unit for particular provinces or diversity in the number of hospital beds per one blood unit for provinces. Then there will be formed the synthetic development measure of provinces on the basis of Hellwig's synthetic development measure. Assumed that determined development measure will illustrate overall situation of blood donation in particular province